Plasma Oxytocin Changes in Response to Low-dose MDMA vs. Placebo in Patients With Arginine Vasopressin Deficiency (Central Diabetes Insipidus) and Healthy Controls - the OxyMAX Study
The investigator hypothesize that low-dose MDMA (3,4-methylenedioxymethamphetamine) will produce a sufficiently strong oxytocin stimulation in healthy controls and no relevant increase in patients. This study will confirm previously published data and provide important safety data with low-dose MDMA stimulation testing.
- Status
- recruiting
- Institution
- University Hospital, Basel, Switzerland
- Principal investigator
- Mirjam Christ-Crain, Prof.
- Start date
- 2025-01-27
- End date
- 2026-12-01
- Registry ID
- NCT06789705
Tracked by the DMT Code Clinical Trials Observatory, an open record of DMT-related clinical research.